Viemed Healthcare, Inc. reported first-quarter 2026 earnings per share of $0.06 on Wednesday [1].
The results indicate a miss against analyst expectations, potentially impacting investor confidence in the company's short-term growth trajectory.
Earnings per share came in at $0.06 [1], falling short of the consensus estimate of $0.09 per share [1]. This figure matches the EPS reported by the company a year ago [1]. Despite the quarterly miss, the company provided updated financial targets for the remainder of the year.
Viemed set its net revenue guidance for 2026 between $312 million and $320 million [2]. The company also projected adjusted EBITDA guidance for 2026 to be between $65 million and $69 million [2].
Executives highlighted “consistent execution” across its platform, led by continued growth in sleep therapy, they said [3]. This focus on sleep therapy is a central part of the company's current operational strategy to drive expansion.
Looking ahead, the company expects sequential revenue growth of three to five percent per quarter for the rest of the year [2]. Prior to the earnings release, consensus revenue estimates for the first quarter had been set at $74 million [4].
The company's financial details were shared via a conference call, with a replay made available on the Viemed Investor Relations website [5].
“Earnings per share came in at $0.06, falling short of the consensus estimate of $0.09 per share.”
The gap between Viemed's reported EPS and analyst expectations suggests a period of stagnation in profitability compared to the previous year. However, the company's commitment to a steady 3% to 5% quarterly revenue growth indicates a strategy of incremental scaling rather than aggressive expansion, relying heavily on the sleep therapy sector to stabilize its financial platform.
